Jefferies Believes UnitedHealth (NYSE: UNH) Still Has Room to Grow

By Carrie Williams

In a report released yesterday, David Steinberg from Jefferies reiterated a Buy rating on UnitedHealth (NYSE: UNH), with a price target of $192. The company’s shares closed yesterday at $172.59, close to its 52-week high of $176.14.

According to, Steinberg is a 4-star analyst with an average return of 3.8% and a 51.9% success rate. Steinberg covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Spectrum Pharmaceuticals, and Supernus Pharmaceuticals.

Currently, the analyst consensus on UnitedHealth is Strong Buy and the average price target is $191, representing a 10.7% upside.

In a report issued on May 17, Leerink Swann also maintained a Buy rating on the stock.

UnitedHealth’s market cap is currently $166.5B and has a P/E ratio of 21.49. The company has a book value ratio of 3.9746.

Based on the recent corporate insider activity of 148 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Richard Burke, a Director at UNH sold 47,500 shares for a total of $8,226,525.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.